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Abstract 
Background: Recent findings suggest that the serotonergic system and particularly the 5-
HT2A/1A receptors are implicated in visual processing and possibly the pathophysiology of 
visual disturbances including hallucinations in schizophrenia and Parkinson’s disease.  
 
Methods: To investigate the role of 5-HT2A/1A receptors in visual processing the effect of the 
hallucinogenic 5-HT2A/1A agonist psilocybin (125 and 250 μg/kg vs placebo) on the 
spatiotemporal dynamics of modal object completion was assessed in normal volunteers (n=17) 
using visual evoked potential (VEP) recordings in conjunction with topographic-mapping and 
source-analysis. These effects were then considered in relation to the subjective intensity of 
psilocybin-induced visual hallucinations quantified by psychometric measurement.  
 
Results: Psilocybin dose-dependently decreased the N170 and, in contrast, slightly enhanced the 
P1 component selectively over occipital electrode sites. The decrease of the N170 was most 
apparent during the processing of incomplete object figures. Moreover, during the time period of 
the N170 the overall reduction of the activation in the right extrastriate and posterior parietal 
areas correlated positively with the intensity of visual hallucinations. 
 
Conclusions: These results suggest a central role of the 5-HT2A/1A-receptors in the modulation 
of visual processing. Specifically, a reduced N170 component was identified as potentially 
reflecting a key process of 5-HT2A/1A receptor–mediated visual hallucinations and aberrant 
modal object completion potential.  
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Introduction 
Despite the fact that the visual and serotonergic systems are among the most explored research 
topics in neuroscience, there is sparse information about the role of serotonin (5-HT) in visual 
processing. However, the high expression of the 5-HT1A (1,2) and 5-HT2A receptors (3-5) in the 
visual areas V1, V2, V3 and lateral suprasylvian cortex (LS) suggest a central role of the 5-HT1A 
and 2A receptors in visual processing. Furthermore, 5-HT2A receptors have been implicated in 
the pathogenesis of visual hallucinations in Parkinson’s (6-8) and schizophrenic patients (9). In 
support of this view, visual hallucinations in Parkinson’s patients have been associated with 
increased density of 5-HT2A receptors in cortical visual pathways (6,8) and effectively treated 
with the 5-HT2A receptor inverse agonist pimavanserin (7). Moreover, visual disturbances and 
hallucinations induced by the indoleamine hallucinogen psilocybin are predominantly mediated 
by the 5-HT2A receptor (10) and resemble, in phenomenological (11) and behavioural 
measurements (12), visual disturbances found in schizophrenia (13,14). Hence, there is an 
increasingly recognized role for the 5-HT2A receptors in the pathogenesis of visual 
hallucinations, while the brain mechanisms mediating between 5-HT2A receptor activation and 
visual hallucination are still unknown.  
To further characterize the role of the 5-HT2A/1A receptors in visual processing and to 
elucidate possible pathophysiological mechanisms of visual deficits and hallucinations, we 
assessed the effect of the mixed 5-HT2A/1A agonist psilocybin (125 µg/ and 250 µg/kg vs. 
placebo) in healthy volunteers. Electroencephalographic recordings were made while participants 
viewed Kanizsa- and non-Kanizsa-figures (Figure 1). Behavioural responses were recorded and 
high-density electrical mapping with source-analysis was used. This allowed for measurement of 
the spatiotemporal brain dynamics of visual modal object completion and its association with the 
appearance of visual hallucinations. 
Modal object completion refers to the illusory perception of object boundaries and their 
enclosing surface in the absence of any direct sensory information depicting these boundaries or 
surfaces. The brain’s ability to interpolate the existence of object surface boundaries is essential 
for accurate object recognition in situations where only ambiguous or incomplete retinal 
information of the object is available (i.e. due to partial occlusion or poor illumination). Modal 
completion has been of particular interest to vision scientists as it is critical for the accurate 
perception of objects and the delineation of multiple objects from themselves or their 
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background. Imaging studies provide strong evidence that the intermediate lateral occipital 
complex (LOC) as well as the early visual area V2 are likely to play a major role in modal 
completion (15-18), while the involvement of the primary visual cortex is more contentious (19). 
Electrophysiological studies revealed that modal object completion of simple figures such as 
Kanizsa-figures is predominantly indexed by the modulation of the N170 component (20-25), 
which appears to be driven primarily by the two critical processes underlying modal object 
completion, boundary-completion (22) and region-based-segmentation (25). In some previous 
studies the presentation of Kanizsa-figures, compared to control figures, have additionally been 
associated with an enhancement of the earlier P1 (26) and the subsequent closure negativity (Ncl) 
component (22). However, as the Ncl component is more reliably induced by more complex 
fragmented images and reflects successful recognition of complex images (27,28) it is unlikely to 
be as relevant to the processing of the simple Kanizsa-figures used in the current experiment. 
The high density of 5-HT1A (1,2) and 5-HT2A (3-5) receptors in LOC and V2, as well as 
the strong activation seen in these areas after psilocybin administration during resting state (29) 
suggest that psilocybin might influence modal object completion. As these processes are so 
critical in defining one’s perceptual experience, this study aims to characterize and understand 
the means by which 5-HT2A/1A receptor activity can alter this fundamental aspect of visual 
experience. 
 
 
Methods and Materials 
Subjects 
Healthy right-handed subjects (8 males, 9 females, mean age 28.8 +/- 3.5 years) were recruited 
through advertisement from the University of Zürich. All subjects were healthy according to 
physical examination including electrocardiography, hematogram and detailed blood analysis. 
The DIA-X diagnostic expert system (30) and a clinical interview was used to exclude subjects 
with present or antecedent psychiatric disorders, regular alcohol or substance abuse and a history 
of major psychiatric disorders in first degree relatives. The screening procedure was 
supplemented by the Freiburg Personality Inventory FPI (31) and Hopkins Symptom Checklist 
SCL-90-R (32) and a self made substance consumption questionnaire. Since the personality trait 
factor “emotional lability” was identified to be a predictor for negative experiences during 
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hallucinogen-induced altered states of consciousness (33), scores exceeding the mean value of 
normative FPI data by two SD were also used as exclusion criterion. Twelve participants reported 
having previous experience with psilocybin or other hallucinogens (mean life time experiences 
5.5 +/- 4.7 times). None of the subjects consumed any psychoactive substance except alcohol, 
nicotine, cannabis and caffeine more than once a year.  
After being informed by a written and oral description of the procedures of the study and 
the effects and possible risks of PY administration, all volunteers gave written informed consent 
to participate in this study. The study was approved by the ethics committee of the University 
Hospital of Psychiatry, Zurich, and the use of psilocybin in humans was authorized by the Swiss 
Federal Office for public health. 
 
Substance and dosing 
Psilocybin was obtained through the Swiss Federal Office for Public Health. The psilocybin high-
dose (HD, 250 mg/kg), low-dose (LD, 125 mg/kg), and lactose placebo (PL) were administered 
in gelatine capsules of identical number and appearance. On three experimental days, separated 
from each other by at least two weeks, the subjects came to the lab at 9 am and confirmed they 
had not eaten breakfast or taken caffeine that morning. In a cross-over randomised design, all 
subjects received placebo and the two graded doses of psilocybin. 
 
Stimulus and Procedure 
The Kanizsa experiment started 120 min post-drug ingestion. During the experiment Kanizsa-
figures and control figures were presented at a distance of 1 meter from the participants while 
they remained fixated on a central fixation-cross. All stimuli consisted of three “pacmen”, each 
composed of a black circle with a sector of 60 degrees removed. The removed sectors were either 
aligned such that the stimulus types induced the perception of an illusory triangle or they were 
rotated by 180 degrees so as to no longer induce the illusory triangle percept (‘Kanizsa’ and ‘non-
Kanizsa’ conditions respectively; see Figure 1). The stimuli subtended a visual angle of 3.7° and 
the support ratio, the ratio of the inducing length to the total length of one illusory contour of the 
triangle, was 1:2. In order to reduce habituation, the stimuli were presented in four different 
orientations of equal number, rotated 0°, 90°, 180°, and 270°. 
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A total of 88 Kanizsa-figures and 88 non-Kanizsa-figures were presented with a stimulus 
onset asynchrony (SOA) of 3 seconds in a pseudorandomized order in two blocks consisting of 
44 Kanizsa-figures and 44 non-Kanizsa-figures each. Participants were required to respond, as 
quickly as possible, with a button press according to whether or not they saw an illusory triangle 
on each trial. The response finger was counterbalanced across the subjects to control for faster 
reaction times of index finger compared to middle finger of the dominant hand. Stimuli remained 
on the monitor for 300 msec after button-press or for a maximum of 2000 msec.  
 
Psychometry 
The Altered States of Consciousness (5D-ASC) rating scale (34) was used to asses the subjective 
effects of placebo and psilocybin with a primary focus on visual alterations and hallucinations. 
The 5D-ASC is a visual-analogue scale consisting of 94 items that measure etiology independent 
alterations in consciousness, including changes in mood, perception, cognition and experience of 
self and of the environment. The five main factors are: (1) Oceanic Boundlessness, measuring 
derealization and depersonalization accompanied by changes in affect ranging from heightened 
mood to euphoria, and alterations in the sense of time. (2) Anxious Ego Dissolution measuring 
ego-disintegration associated with loss of self-control, thought disorder, arousal, and anxiety. (3) 
Visionary Restructuralization (VR) assessing visual illusions and (pseudo-) hallucinations, which 
includes the whole spectrum ranging from elementary to complex hallucinations. (4) Auditory 
Alterations (AA) comprising auditory illusions and (pseudo-) hallucinations. (5) Reduction of 
Vigilance assessing changes in vigilance and alertness. The results of the 5D-ASC data are given 
as percentage scores of maximum absolute scale values. 
 
EEG recording 
EEG recordings were made using BioSemi ActiveTwo electrode system with 64 scalp electrodes. 
Additional electrodes were attached on the outer canthus of each eye to record the horizontal 
electroocculogram (EOG) and infraorbitally and supraorbitally to the left eye to record the 
vertical EOG. Electrophysiological signals were band-pass filtered at 0.01-67 Hz and digitized at 
256 Hz. 
 
EEG analysis 
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EEG data were recalculated offline against average reference and band-pass filtered at 1-40 Hz. 
Correct response trials were segmented from -150 to +600 ms relative to stimulus presentation. 
To avoid eye movement and other artifacts in further analysis, epochs exceeding ±100 µV in any 
channel were excluded. The mean +/- SD number of accepted epochs per condition was 85.0 +/- 
5.4 for Kanizsa placebo, 85.0 +/- 3.0 for non-Kanizsa placebo, 82.9 +/- 4.6 for Kanizsa low-dose, 
83.2 +/- 3.7 for non-Kanizsa low-dose, 78.8 +/- 9.4 for Kanizsa high-dose, 79.4 +/- 9.8 for non-
Kanizsa high-dose. These epochs were averaged time-locked to Kanizsa- and non-Kanizsa-figure 
presentation time to compute the VEP. The 600 ms poststimulus period of the VEP underwent 
three different analyses to reveal the VEP waveforms, the scalp topography and the source 
localization. This combination of analysis methods has been increasingly used during the last 
years, as it reduces experimenter bias associated with the selection of the appropriate time 
window for statistical analysis of the components (35). 
Waveform analysis: To quantify waveform modulations, five symmetrical pairs of 
electrodes were selected over the maxima of the scalp topographies for the P1 and N170 
components (PO7/PO8, PO3/PO4, O1/O2, P1/P2, P3/P4). The specific time windows used for 
calculation of the mean amplitude (versus the baseline) were determined by the topographic 
analysis described below. The mean amplitudes of each of these time windows were then 
subjected to separate repeated measures analysis of variance (ANOVA) with the within-subject 
factors dose (PL, LD, HD) electrode (PO7/PO8, PO3/PO4, O1/O2, P1/P2, P3/P4), hemiscalp 
(left, right) and stimulus (Kanizsa, non-Kanizsa). 
Topographic analysis: First a spatial k-means cluster analysis identified the predominant 
topographies (also called template map) appearing in the normalized group-averaged ERPs as a 
function of time and experimental condition (36). This analysis was constrained by the temporal 
criterion, that certain topographies must be observed for at least 5 consecutive data points (> 20 
ms at a 256 Hz sampling rate). The optimal number of topographies that explained the whole 
dataset was determined by a modified cross-validation criterion (36). In a second step we 
statistically verified that maps identified at the group-averaged level also appeared on the 
individual subject level. Therefore, at each time point the topography of the individual subjects’ 
ERP was compared by means of strength-independent spatial correlation to all template maps and 
was labeled according to the one with which it best correlated (35,37). This revealed values of 
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relative map presence (in milliseconds), which were then subjected to a repeated measures 
ANOVA using stimulus condition, map and dose as within-subject factors.   
Source Localization: Standardized low-resolution electromagnetic tomography 
(sLORETA) was used to estimate the three dimensional intra-cerebral current density 
distributions underlying the ERPs within the time frames defined by topographic analysis. 
sLORETA offers a solution of the inverse problem by assuming that the smoothest of all possible 
activity is the most plausible one (38). The solution space of sLORETA (i.e. the lead field matrix) 
includes 6239 voxels and was computed with a three-shell spherical head model registered to the 
neuroanatomical atlas of Talairach and Tournoux (Brain Imaging Centre, Montreal Neurological 
Institute).  
Correlational analyses were performed to determine whether psilocybin-induced changes 
in the current source density within the time frames defined by topographic analysis were related 
to visual or auditory hallucinations. First, the differences of the current source density between 
psilocybin conditions (low- and high-dose) and placebo were calculated separately. In a second 
step these data were pooled and the product-moment correlations between these differences and 
the VR and AA scores, respectively, were calculated for each voxel. Significant correlations were 
identified using nonparametric permutation testing (39) that determined the critical probability 
threshold values for the observed r-values with correction for multiple testing.  
 
Results 
Psychometrics 
The subjective effects of psilocybin were assessed by the 5D-ASC rating scale. Repeated 
measures ANOVA revealed a significant main effect of dose (F(2,32)=36.596, p<0.00001, 
η2=0.70), factor (F(4,64)=12.924, p<0.00001, η2=0.45) and dose x factor interaction 
(F(8,128)=7.09, p<0.00001, η2=0.31) . Bonferroni-corrected post-hoc analysis on the VR factor, 
which was of primary interest in regard to the current study, indicated a significant increase 
between placebo and low-dose psilocybin (p<0.00001) as well as placebo and high-dose 
psilocybin (p<0.00001) but not low-dose and high-dose psilocybin (p=0.178). Bonferroni-
corrected post-hoc analysis on the AA factor revealed a significant increase between placebo and 
high-dose psilocybin (p<0.05) but not placebo and low-dose psilocybin (p=1.0).   
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Behavioral data 
Reaction time was dose-dependently increased by psilocybin (F(2,32)=18.841, p<0.00001, 
η2=0.54) and was generally faster for Kanizsa- compared to non-Kanizsa-figure (F(1,16)=36.037, 
p<0.0001, η2=0.69) (Table 1). While psilocybin administration did lead to a dose-dependent 
increase in error rates (F(2,32)=3.3291, p<0.05, η2=0.17), the error rates remained very low in all 
conditions (0.88% for placebo, 1.18% for low-dose, 1.92% for high-dose). We are therefore 
confident that participants were able to do the task under all drug conditions.  
 
Electrophysiological data 
Under all 3 drug conditions both stimuli elicited prominent VEP, including the P100 and N170 
component (Figure 1) with a maximum over lateral occipital scalp areas (Figure 3). The 
subsequent topographic analysis detected nine different scalp topographies, which accounted for 
the 600 ms post-stimulus periods across all conditions with a global explained variance (GEV) of 
96.74 %. The first three time periods of stable scalp topographies were identical across conditions 
lasting from 0-86 ms, 90-144 ms, 148-223 ms (Figure S1). These time periods were used to 
define the time window for quantifying the P1 and N170 VEP in a more objective manner 
(Murray et al., 2008) and for the subsequent source localization and correlation analysis 
(Analysis referring to the P300 component can be found in supplementary material).   
 
P1  
During the time-range of the P1 component (90-144 ms) a 3 x 2 x 5 x 2 repeated measures 
ANOVA (using dose, hemiscalp, electrode, and stimulus as within factors) revealed only a main 
effect of electrode (F(4, 64)=33.42, p<0.00001, η2=0.68) and a significant interaction of electrode 
and dose (F(8, 128)=3.43, P<0.01, η2=0.18). Performing bonferroni-corrected post-hoc analysis 
of this interaction, the P1 amplitude was found to be significantly increased from placebo only at 
the O1/O2 electrodes by low dose (p < 0.05) and high dose (p < 0.0001) psilocybin. No effect of 
psilocybin was observed at other electrodes, nor did any other interaction reach significance. This 
result indicates that the effect of psilocybin on the P1 component is locally restricted to occipital 
electrode sites and is independent of hemiscalp and stimulus condition (Figure 2). Furthermore, 
neither the main effect for dose (F(2,32)=0.95, p=0.39, η2=0.06), stimulus (F(1,16)=0.77, p=0.39, 
η2=0.05) nor hemiscalp (F(1,16)=1.71, p=0.21, η2=0.10) reached significance. 
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To further elucidate topographic modulation of the P1 component, the spatial correlation 
procedure was used first to assess the number of time frames a given topography from the group-
averaged data was present in a given condition across subjects (see methods). These values were 
subjected to a repeated measures ANOVA (using dose, stimulus, and map as within factors), 
which provided no evidence of topographic specificity to one stimulus or dose condition (all P’s 
> 0.15). 
Source estimation from the 90-144 ms period yielded activity within LOC and V2 in both 
hemispheres across all conditions. The psilocybin-induced increase in the P1 component over 
O1/O2 electrode sites seen in the VEP waveform-analysis was localized most strongly in V2 and 
extended to LOC and V1 in the right hemisphere in the high-dose condition. The psilocybin 
induced increase in the source-density did neither correlate with visual (all P’s > 0.17) nor with 
auditory hallucinations (all P’s > 0.98). 
 
N170 
To quantify the modulation of the N170 component, area measurements over the 148-223 ms 
period were subjected to a 3 x 2 x 5 x 2 repeated measures ANOVA (using dose, hemiscalp, 
electrode, and stimulus as within factors). Psilocybin dose-dependently decreased the N170 
amplitude (F(2,32)=17.170, p<0.00001, η2=0.52) and bonferroni-corrected post-hoc analysis 
revealed that the magnitude differences were significant between all dose conditions (Figure 2). 
The significant interaction between dose and hemiscalp (F(2,32)=5.30, p<0.05, η2=0.25) and the 
visual inspection of the VEP indicated a stronger psilocybin-induced decrease over the right 
compared to the left hemiscalp. In accordance with numerous previous studies (20-25) a 
significant main effect of the stimulus condition was observed (F(1,16)=35.863, p<0.0001, 
η2=0.70), with a greater magnitude in the Kanizsa- compared to the non-Kanizsa-condition. This 
magnitude difference between Kanizsa- and non-Kanizsa conditions dose-dependently decreased 
as revealed by the significant interaction between dose and condition (F(2,32)=3.4485, p<0.05, 
η2=0.18).  
The topographic pattern analysis of the collective data indicated that the effects of 
strength modulation in the electrical field were not associated with topographic modulations. This 
was subsequently confirmed by subjecting individual subject data to repeated measures ANOVA 
(all P’s > 0.25).  
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The source estimation revealed activity within LOC and V2 in both hemispheres in all 
conditions (Figure 3). Current source density was stronger within right-lateralized LOC and V2 
in the Kanizsa- compared to non-Kanizsa-condition. Psilocybin dose-dependently decreased the 
differential activation of the two stimulus conditions and reduced the current source density 
within LOC, V2 and fusiform gyrus in both stimulus conditions. The psilocybin-induced current 
source density reduction over right-lateralized LOC, V2 and posterior parietal areas correlated 
significantly with the increased intensity of visual hallucinations (Figure 4), while no correlation 
could be revealed with auditory hallucinations (all Ps > 0.64).  
 
Discussion 
The present investigation revealed three main findings. First, the data indicate that the mixed 5-
HT2A/1A-receptor agonist psilocybin distinctively modulates the two early visual processing 
components. Specifically, while we found a strong dose-dependent decrease of the N170 
component (148-223 ms post-stimulus) the earlier visual P1 component (90-144 ms post-
stimulus) was slightly increased over occipital electrode sites. Second, the reduction of the N170 
component was stronger for the Kanizsa-figure condition as compared to the non-Kanizsa 
condition.  Third, during this time range the decrease in activation over right-lateralized 
extrastriate and posterior parietal cortex correlated with the reported intensity of visual 
hallucinations. 
The time frame of the N170 component has been regarded as a critical period for object 
completion based on numerous findings of enhanced N170 amplitude and underlying LOC and 
V2 activation evoked by Kanizsa- compared to control figures (20-25). The preferential reduction 
of the N170 amplitude in Kanizsa compared to non-Kanizsa condition by psilocybin indicates a 
central role of the 5-HT2A/1A receptors in object-completion. Since two sub-processes of object 
completion, i.e. boundary completion (22) and region-based segmentation (25), have been shown 
to underlay the enhanced N170 amplitude in the Kanizsa-condition, it would be interesting to 
further investigate which of these two sub-processes is modulated by signal transmission at 5-
HT2A/1A receptors.  
The finding that psilocybin slightly enhanced P1 amplitude may reflect a generalized 
effect of 5-HT2A/1A mediated increase in perceived brightness which is often reported after 
indolamine hallucinogen administration (40). This is supported by previous studies using 
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comparable Kanizsa-figures showing the P1 component to be sensitive to stimulus brightness 
(41) as well as eccentricity (20) and symmetry (41). 
Given that psilocybin strongly decreased the N170 amplitude in both the Kanizsa and the 
non-Kanizsa conditions, we suggest that it modulates additional processes beyond proper object 
completion. Disruption of these processes might play a role in visual hallucinations, since their 
reported intensity was significantly correlated with the 3-dimensional current source density 
reduction over right-lateralized LOC, V2 and posterior parietal areas during the time-frame of the 
N170 component. This localization is in agreement with previous imaging studies reporting 
decreased extrastriate activation in response to external visual stimuli in patients with visual 
hallucinations compared to patients without hallucinations (42-44). Furthermore, we found 
decreased activation specifically during the time-range of the N170 component. Decreased 
activation during this time range has been previously reported in studies investigating acoustic 
(45,46) and visual hallucinations (23). We therefore suggest that decreased stimulus-induced 
activation in modality-specific cortical areas during the time range of the N1/ N170 component 
may be a characteristic of acoustic as well as visual hallucinations. This relationship between the 
increased intensity of visual hallucinations and the decreased stimulus-evoked activation of 
extrastriate areas during the time-range of the N170 component could reflect a competition for 
neuronal resources in the processing of internally (hallucination) and externally (sensory-driven) 
generated information (46,47). A comparable mechanism has previously been suggested to be 
relevant in the formation of acoustic hallucinations (48). Increased extrastriate activation which 
could interfere with the processing of external stimuli, has been observed previously during 
visual hallucinations in the absence of external stimulation in different psychiatric disorders 
(43,49-51) as well as after psilocybin administration (29). In line with this interpretation we 
additionally found a correlation between reduced posterior parietal activation and hallucinatory 
severity. The posterior parietal cortex controls attention to visual stimuli by modulating visual 
cortex activity (52) during the time-range of the N170 component (53). The reduced posterior 
parietal activation might therefore reflect a psilocybin-induced failure to allocate attention and 
thus neuronal resources to external stimuli.  
Importantly, we identified reduced extrastriate visual cortex activation during the time 
range of the N170 as a potential key component of 5-HT2A/1A agonist-induced visual 
hallucinations. Such a mechanism could also underlie the visual disturbances and hallucinations 
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reported in Parkinson and schizophrenia patients, since increased 5-HT2A receptor densities have 
been found in these conditions and associated with visual hallucinations (6,8,9). In support of this 
notion, Parkinson’s patients with visual hallucinations showed more pronounced impairments in 
visual object recognition (54,55) and more prominent reductions in extrastriate cortex activation 
to visual stimuli than patients without hallucinations (44). Moreover, a reduction of the N170 
component has also been reported in schizophrenia patients and associated with visual 
hallucinations using Kanizsa-figures (23). These observations are in line with our finding of a 
correlation between reduced extrastriate activation during the time range of the N170 component 
and the intensity of visual hallucinations. It is noteworthy, however, that two other previous 
studies using Kanizsa-figures in schizophrenia reported either no reduction (24) or only a 
reduction at a trend level (56). The apparent discrepancy between these results and our findings 
may be due to the fact that only about 30% of schizophrenia patients typically report visual 
hallucinations (57) and many of the patients tested were medicated with atypical antipsychotics 
with 5-HT2A antagonistic activity. It might, therefore be possible that a disrupted 5-HT2A 
receptor system may be relevant only to a subgroup of schizophrenia patients. Given that we did 
not find a decrease of the P1 component after psilocybin administration and the robust reduction 
of the P1 component reported in schizophrenia (23,24,56,58) was not associated with psychotic 
symptoms (58) suggests that the reduction of the P1 component in schizophrenia is not related to 
serotonergic alterations and may rather represent an endophenotype of the schizophrenia 
spectrum (58,59). 
Since psilocybin is a mixed 5-HT2A/1A agonist (60) resulting in downstream effects on 
the dopamine systems (61), the exact pharmacological mechanisms of the observed psilocybin 
effects require further investigation. However, converging lines of evidence indicate that 
psilocybin’s psychotomimetic effects are mediated through the 5-HT2A-receptor activation 
(10,62). For example, behavioral effects of psilocybin are lacking in 5-HT2A receptor knockout 
mice (63) and in humans nearly all psychotomimetic effects including visual distortions and 
hallucinations can be blocked by the 5-HT2A antagonist ketanserin (64,65), but not by blocking 
downstream dopaminergic effects with haloperidol (64). These findings, in combination with 
evidence regarding the importance of the 5-HT2A receptors in the pathophysiology of visual 
hallucinations (6-9), indicate that the reported effects of psilocybin are likely to be mediated by 
5-HT2A receptor activation.  However, given that 5-HT1A receptors additionally influence the 
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psychotomimetic effects of indolamine hallucinogens (66) and 5-HT1A receptors are widespread 
in the visual cortex (1,2), further studies are needed to exclude an additional contribution of 5-
HT1A receptor on the spatiotemporal dynamics of visual object completion and hallucinations.  
 
Figure Legends 
 
 
Figure 1 
A) Example of Kanizsa-figure and non-Kanizsa-figure. B) Group-averaged VEP waveforms in 
response to Kanizsa-figures (black traces) and non-Kanizsa-figures (red traces) for placebo, low-
dose and high-dose condition averaged from the left and right posterior electrode sites PO7/PO8, 
where P1 and N170 amplitude was most pronounced. Dashed lines indicate the time period of 
stable topographic configuration of the P1 and N170 component.  
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Figure 2 
The bar graphs display mean areas of the P1 (top) and N170 (bottom) components measured from 
10 parieto-occipital electrodes sites (left) and from occipital electrode sites O1/O2 (right) 
symmetrically localized over both hemiscalps (see Methods and Materials for details). Mean 
areas are displayed for Kanizsa-figures (black) and non-Kanizsa-figures (red) for all dose 
conditions (PL = placebo, LD = low-dose, HD = high-dose). Vertical bars denote standard 
deviations. The y axis presents amplitude in microvolts (µV).  
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Figure 3 
A) Group-averaged LORETA source estimations for each stimulus (Kanizsa, non-Kanizsa) and 
dose (PL = placebo, LD = low-dose, HD = high-dose) conditions over the N170 period (148-223 
ms). B) Group-averaged differences of the source estimations between Kanizisa and non-Kanizsa 
condition.  
 
 
Figure 4 
The voxel-wise correlation between visual hallucinations and placebo - psilocybin current source 
density difference revealed that psilocybin-induced decrease in current source density in right 
extrastriate areas and posterior parietal areas over the N170 period (148-223 ms) positively 
correlated with the intensity of visual hallucinations (significant areas p < 0.05 are shown in red). 
194 voxels reached 0.05 significance criterion with a mean r value of 0.57.  
 
Kometer et al. 16
 
Acknowledgment 
This work was supported by the Swiss Neuromatrix Foundation, Switzerland (M.K., F.X.V) and 
the Heffter Research Insititute, Santa Fe, USA, (R.C., D.A.). We express our appreciation to R.D. 
Pascual-Marqui for his technical support and for the development of LORETA software package.  
 
Financial Disclosure 
All authors report no financial interests or potential conflicts of interest with respect to this study. 
 
References 
 
 1.  Dyck RH, Cynader MS (1993): Autoradiographic localization of serotonin receptor 
subtypes in cat visual cortex: transient regional, laminar, and columnar distributions 
during postnatal development. J Neurosci 13: 4316-4338. 
 2.  Gerstl F, Windischberger C, Mitterhauser M, Wadsak W, Holik A, Kletter K et al (2008): 
Multimodal imaging of human early visual cortex by combining functional and molecular 
measurements with fMRI and PET. Neuroimage 41: 204-211. 
 3.  Jakab RL, Goldman-Rakic PS (1998): 5-Hydroxytryptamine2A serotonin receptors in the 
primate cerebral cortex: Possible site of action of hallucinogenic and antipsychotic drugs 
in pyramidal cell apical dendrites. Proc Natl Acad Sci 95: 735-740. 
 4.  Adams KH, Pinborg LH, Svarer C, Hasselbalch SG, Holm S, Haugbol S et al (2004): A 
database of (18F)-altanserin binding to 5-HT2A receptors in normal volunteers: 
normative data and relationship to physiological and demographic variables. Neuroimage 
21: 1105-1113. 
 5.  Watakabe A, Komatsu Y, Sadakane O, Shimegi S, Takahata T, Higo N et al (2009): 
Enriched expression of serotonin 1B and 2A receptor genes in macaque visual cortex and 
their bidirectional modulatory effects on neuronal responses. Cereb Cortex 19: 1915-
1928. 
Kometer et al. 17
 6.  Ballanger B, Strafella AP, van ET, Zurowski M, Rusjan PM, Houle S et al (2010): 
Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 67: 
416-421. 
 7.  Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D et al (2010): 
Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's 
disease psychosis. Neuropsychopharmacology 35: 881-892. 
 8.  Huot P, Johnston TH, Darr T, Hazrati LN, Visanji NP, Pires D et al (2010): Increased 5-
HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. 
Mov Disord 25: 1399-1408. 
 9.  Gonzalez-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, Lopez-Gimenez JF et al 
(2008): Identification of a serotonin/glutamate receptor complex implicated in psychosis. 
Nature 452: 93-97. 
 10.  Geyer MA, Vollenweider FX (2008): Serotonin research: contributions to understanding 
psychoses. Trends Pharmacol Sci 29: 445-453. 
 11.  Vollenweider FX, Geyer MA (2001): A systems model of altered consciousness: 
Integrating natural and drug-induced psychoses. Brain Res Bull 56: 495-507. 
 12.  Carter OL, Pettigrew JD, Burr DC, Alais D, Hasler F, Vollenweider FX (2004): 
Psilocybin impairs high-level but not low-level motion perception. NeuroReport 15: 
1947-1951. 
 13.  Chen Y, Levy DL, Sheremata S, Holzman PS (2004): Compromised late-stage motion 
processing in schizophrenia. Biol Psychiatry 55: 834-841. 
 14.  Chen Y, Nakayama K, Levy D, Matthysse S, Holzman P (2003): Processing of global, but 
not local, motion direction is deficient in schizophrenia. Schizophr Res 61: 215-227. 
 15.  Mendola JD, Dale AM, Fischl B, Liu AK, Tootell RB (1999): The representation of 
illusory and real contours in human cortical visual areas revealed by functional magnetic 
resonance imaging. J Neurosci 19: 8560-8572. 
Kometer et al. 18
 16.  Halgren E, Mendola J, Chong CD, Dale AM (2003): Cortical activation to illusory shapes 
as measured with magnetoencephalography. Neuroimage 18: 1001-1009. 
 17.  Stanley DA, Rubin N (2003): fMRI activation in response to illusory contours and salient 
regions in the human Lateral Occipital Complex. Neuron 37: 323-331. 
 18.  Montaser-Kouhsari L, Landy MS, Heeger DJ, Larsson J (2007): Orientation-selective 
adaptation to illusory contours in human visual cortex. J Neurosci 27: 2186-2195. 
 19.  Seghier ML, Vuilleumier P (2006): Functional neuroimaging findings on the human 
perception of illusory contours. Neuroscience and Biobehavioral Reviews 30: 595-612. 
 20.  Murray MM, Wylie GR, Higgins BA, Javitt DC, Schroeder CE, Foxe JJ (2002): The 
spatiotemporal dynamics of illusory contour processing: Combined high-density electrical 
mapping, source analysis, and functional magnetic resonance imaging. J Neurosci 22: 
5055-5073. 
 21.  Murray MM, Foxe DM, Javitt DC, Foxe JJ (2004): Setting boundaries: brain dynamics of 
modal and amodal illusory shape completion in humans. J Neurosci 24: 6898-6903. 
 22.  Murray MM, Imber ML, Javitt DC, Foxe JJ (2006): Boundary completion is automatic 
and dissociable from shape discrimination. J Neurosci 26: 12043-12054. 
 23.  Spencer KM, Nestor PG, Perlmutter R, Niznikiewicz MA, Klump MC, Frumin M et al 
(2004): Neural synchrony indexes disordered perception and cognition in schizophrenia. 
Proc Natl Acad Sci : 1-6. 
 24.  Foxe JJ, Murray MM, Javitt DC (2005): Filling-in in schizophrenia: A high-density 
electrical mapping and source-analysis investigation of illusory contour processing. Cereb 
Cortex 15: 1914-1927. 
 25.  Yoshino A, Kawamoto M, Yoshida T, Kobayashi N, Shigemura J, Takahashi Y et al 
(2006): Activation time course of responses to illusory contours and salient region: A 
high-density electrical mapping comparison. Brain Res 1071: 137-144. 
Kometer et al. 19
 26.  Brodeur M, Lepore F, Lepage M, Bacon BA, Jemel B, Debruille JB (2008): Alternative 
mode of presentation of Kanizsa figures sheds new light on the chronometry of the 
mechanisms underlying the perception of illusory figures. Neuropsychologia 46: 554-566. 
 27.  Doniger GM, Foxe JJ, Murray MM, Higgins BA, Snodgrass JG, Schroeder CE et al 
(2000): Activation timecourse of ventral visual stream object-recognition areas: high 
density electrical mapping of perceptual closure processes. J Cogn Neurosci 12: 615-621. 
 28.  Sehatpour P, Dias EC, Butler PD, Revheim N, Guilfoyle DN, Foxe JJ et al (2010): 
Impaired visual object processing across an occipital-frontal-hippocampal brain network 
in schizophrenia: an integrated neuroimaging study. Arch Gen Psychiatry 67: 772-782. 
 29.  Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997): 
Positron emission tomography and fluorodeoxyglucose studies of metabolic 
hyperfrontality and psychopathology in the psilocybin model of psychosis. 
Neuropsychopharmacology 16: 357-372. 
 30.  Wittchen,HU, Pfister,H  (1997): DIA-X-Interview . Frankfurt: Swets Test Services. 
 31.  Fahrenberg,J, Hampel,R, Selg,H  (1984): Das Freiburger Persönlichkeitsinventar FPI , 4 
ed. Göttingen: Hogrefe. 
 32.  Derogatis,LR  (1994): SCL-90-R: Symptom Checklist-90-R. Administration, scoring and 
procedures manual , 3rd Edition ed. Minneapolis: National Computer Systesm. 
 33.  Dittrich A (1994): Psychological aspects of altered states of consciousness of the LSD 
type: measurements of their basic dimensions and prediction of individual differences. In 
Pletscher A, Ladewig D, editors. 50 Years of LSD. Current Status and Perspectives of 
Hallucinogens, 1 ed. New York: Parthenon Publishing, pp 101-118. 
 34.  Dittrich A (1998): The standardized psychometric assessment of altered states of 
consciousness (ASCs) in humans. Pharmacopsychiat 31: 80-84. 
 35.  Murray MM, Brunet D, Michel CM (2008): Topographic ERP analyses: a step-by-step 
tutorial review. Brain Topogr 20: 249-264. 
Kometer et al. 20
 36.  Pascual-Marqui RD, Michel CM, Lehmann D (1995): Segmentation of brain electrical 
activity into microstates: model estimation and validation. IEEE Trans Biomed Eng 42: 
658-665. 
 37.  Brandeis D, Lehmann D, Michel CM, Mingrone W (1995): Mapping event-related brain 
potential microstates to sentence endings. Brain Topogr 8: 145-159. 
 38.  Pascual-Marqui RD (2002): Standardized low-resolution brain electromagnetic 
tomography (sLORETA): technical details. Methods Find Exp Clin Pharmacol 24 Suppl 
D: 5-12. 
 39.  Nichols TE, Holmes AP (2002): Nonparametric permutation tests for functional 
neuroimaging: a primer with examples. Hum Brain Mapp 15: 1-25. 
 40.  Siegel RK, Jarvik ME (1975): Drug-induced hallucinations in animals and man. In Siegel 
RK, West LJ, editors. Hallucinations. Behavior, Experience & Theory. New York: John 
Wiley & Sons, pp 81-161. 
 41.  Proverbio AM, Zani A (2002): Electrophysiological indexes of illusory contours 
perception in humans. Neuropsychologia 40: 479-491. 
 42.  Howard R, Williams S, Bullmore E, Brammer M, Mellers J, Woodruff P et al (1995): 
Cortical response to exogenous visual stimulation during visual hallucinations. Lancet 
345: 70. 
 43.  Ffytche DH, Howard RJ, Brammer MJ, David A, Woodruff P, Williams S (1998): The 
anatomy of conscious vision: an fMRI study of visual hallucinations. Nature Neurosci 1: 
738-742. 
 44.  Meppelink AM, de Jong BM, Renken R, Leenders KL, Cornelissen FW, van LT (2009): 
Impaired visual processing preceding image recognition in Parkinson's disease patients 
with visual hallucinations. Brain 132: 2980-2993. 
Kometer et al. 21
 45.  Tiihonen J, Hari R, Naukkarinen H, Rimon R, Jousmäki V, Kajola M (1992): Modified 
activity of the human auditory cortex during auditory hallucinations. Am J Psychiatry 
149: 255-257. 
 46.  Hubl D, Koenig T, Strik WK, Garcia LM, Dierks T (2007): Competition for neuronal 
resources: how hallucinations make themselves heard. Br J Psychiatry 190: 57-62. 
 47.  Allen P, Laroi F, McGuire PK, Aleman A (2008): The hallucinating brain: a review of 
structural and functional neuroimaging studies of hallucinations. Neurosci Biobehav Rev 
32: 175-191. 
 48.  Ford JM, Roach BJ, Jorgensen KW, Turner JA, Brown GG, Notestine R et al (2009): 
Tuning in to the voices: a multisite FMRI study of auditory hallucinations. Schizophr Bull 
35: 58-66. 
 49.  Silbersweig DA, Stern E, Frith GH, Cahill C, Holmes A, Grootoonk S et al (1995): A 
functional neuroanatomy of hallucinations in schizophrenia. Nature 378: 176-179. 
 50.  Holroyd S, Wooten GF (2006): Preliminary FMRI evidence of visual system dysfunction 
in Parkinson's disease patients with visual hallucinations. J Neuropsychiatry Clin 
Neurosci 18: 402-404. 
 51.  Oertel V, Rotarska-Jagiela A, van dV, V, Haenschel C, Maurer K, Linden DE (2007): 
Visual hallucinations in schizophrenia investigated with functional magnetic resonance 
imaging. Psychiatry Res 156: 269-273. 
 52.  Bressler SL, Tang W, Sylvester CM, Shulman GL, Corbetta M (2008): Top-down control 
of human visual cortex by frontal and parietal cortex in anticipatory visual spatial 
attention. J Neurosci 28: 10056-10061. 
 53.  Rose M, Schmid C, Winzen A, Sommer T, Buchel C (2005): The functional and temporal 
characteristics of top-down modulation in visual selection. Cereb Cortex 15: 1290-1298. 
Kometer et al. 22
 54.  Meppelink AM, Koerts J, Borg M, Leenders KL, van LT (2008): Visual object 
recognition and attention in Parkinson's disease patients with visual hallucinations. Mov 
Disord 23: 1906-1912. 
 55.  Koerts J, Borg MA, Meppelink AM, Leenders KL, van BM, van LT (2010): Attentional 
and perceptual impairments in Parkinson's disease with visual hallucinations. 
Parkinsonism Relat Disord 16: 270-274. 
 56.  Spencer KM, Nestor PG, Niznikiewicz MA, Salisbury DF, Shenton ME, McCarley RW 
(2003): Abnormal neural synchrony in schizophrenia. J Neurosci 23: 7407-7411. 
 57.  Bracha HS, Wolkowitz OM, Lohr JB, Karson CN, Bigelow LB (1989): High prevalence 
of visual hallucinations in research subjects with chronic schizophrenia. Am J Psychiatry 
146: 526-528. 
 58.  Yeap S, Kelly SP, Sehatpour P, Magno E, Garavan H, Thakore JH et al (2008): Visual 
sensory processing deficits in Schizophrenia and their relationship to disease state. Eur 
Arch Psychiatry Clin Neurosci 258: 305-316. 
 59.  Yeap S, Kelly SP, Sehatpour P, Magno E, Javitt DC, Garavan H et al (2006): Early visual 
sensory deficits as endophenotypes for schizophrenia: high-density electrical mapping in 
clinically unaffected first-degree relatives. Arch Gen Psychiatry 63: 1180-1188. 
 60.  McKenna DJ, Repke DB, Peroutka SJ (1990): Differential interactions of 
indolealkylamines with 5-hydroxytrypamine receptor subtypes. Neuropharmacology 29: 
193-198. 
 61.  Vollenweider,FX, Vontobel,P, Hell,D, and Leenders,KL (1998): 5-HT modulation of 
dopamine release in basal ganglia in psilocybin-induced psychosis in man - a PET study 
with [11C] raclopride. Neuropsychopharmacology 20: 424-433. 
 62.  Gonzalez-Maeso J, Sealfon SC (2009): Psychedelics and schizophrenia. Trends Neurosci 
32: 225-232. 
Kometer et al. 23
 63.  Gonzalez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R et al (2007): 
Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to 
affect behavior. Neuron 53: 439-452. 
 64.  Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A, Vogel H, Hell D 
(1998): Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 
agonist action. NeuroReport 9: 3897-3902. 
 65.  Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX (2005): Using 
psilocybin to investigate the relationship between attention, working memory, and the 
serotonin 1A and 2A receptors. J Cogn Neurosci 17: 1497-1508. 
 66.  Nichols DE (2004): Hallucinogens. Pharmacol Ther 101: 131-181. 
 
 
  
 
